beta-alanine has been researched along with Neoplasms in 19 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation." | 3.80 | [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. ( Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014) |
| "These trials enrolled 5167 people with cancer and VTE." | 2.58 | Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
| "The decision for a patient with cancer and VTE to start long-term LMWH versus oral anticoagulation should balance the benefits and harms and integrate the patient's values and preferences for the important outcomes and alternative management strategies." | 2.50 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Kahale, L; Labedi, N; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I, 2014) |
| " Therefore, the previously identified increased toxicity and shorter survival in patients with a low SMM, could not be explained by changes in pharmacokinetic characteristics of capecitabine and metabolites." | 1.62 | Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Kurk, SA; May, AM; Molenaar-Kuijsten, L; Steeghs, N, 2021) |
| "Dabigatran was administered at a dose of 110-150 mg once or twice daily, depending on the renal function and age." | 1.42 | Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. ( Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y, 2015) |
| " Possible mechanisms by which carnosine may perform its anti-tumourigenic effects are outlined and its expected bioavailability and possible negative and positive side effects are considered." | 1.38 | Carnosine and cancer: a perspective. ( Gaunitz, F; Hipkiss, AR, 2012) |
| "Tumors are visible as early as 0." | 1.32 | Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. ( Barrett, J; Bartis, J; Bozarth, J; Edwards, S; Ellars, C; Harris, TD; Kalogeropoulos, S; Lazewatsky, J; Liu, S; Nguyen, T; Onthank, D; Robinson, S; Silva, P; Yalamanchili, P, 2003) |
| "Some of these solid tumors contain greater amounts of activity than do their normal equivalents, which encourages the use of inhibitors of this enzyme in conjunction with treatment of these tumors by 5-fluorouracil." | 1.27 | Enzymes of uracil catabolism in normal and neoplastic human tissues. ( Cha, S; el Kouni, MH; Naguib, FN, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Molenaar-Kuijsten, L | 1 |
| Jacobs, BAW | 1 |
| Kurk, SA | 1 |
| May, AM | 1 |
| Dorlo, TPC | 1 |
| Beijnen, JH | 1 |
| Steeghs, N | 1 |
| Huitema, ADR | 1 |
| Kahale, LA | 1 |
| Hakoum, MB | 1 |
| Tsolakian, IG | 1 |
| Matar, CF | 1 |
| Terrenato, I | 2 |
| Sperati, F | 2 |
| Barba, M | 2 |
| Yosuico, VE | 1 |
| Schünemann, H | 2 |
| Akl, EA | 2 |
| den Exter, PL | 1 |
| Kooiman, J | 1 |
| van der Hulle, T | 1 |
| Huisman, MV | 1 |
| Bachellerie, B | 1 |
| Ruiz, S | 1 |
| Conil, JM | 1 |
| Crognier, L | 1 |
| Seguin, T | 1 |
| Georges, B | 1 |
| Fourcade, O | 1 |
| Holy, EW | 1 |
| Beer, JH | 1 |
| Kahale, L | 1 |
| Neumann, I | 1 |
| Labedi, N | 1 |
| Muti, P | 1 |
| Fujino, T | 1 |
| Yamazaki, Y | 1 |
| Yamazaki, A | 1 |
| Kabuki, T | 1 |
| Kiuchi, S | 1 |
| Kobayashi, K | 1 |
| Yamazaki, J | 1 |
| Ikeda, T | 1 |
| Budczies, J | 1 |
| Santra, S | 1 |
| Perez, JM | 1 |
| Gaunitz, F | 1 |
| Hipkiss, AR | 1 |
| Tafur, A | 1 |
| Wysokinski, WE | 1 |
| McBane, RD | 1 |
| JACQUEZ, JA | 1 |
| STOCK, CC | 1 |
| BARCLAY, RK | 1 |
| BROWN, RW | 1 |
| GRISOLIA, S | 1 |
| Harris, TD | 1 |
| Kalogeropoulos, S | 1 |
| Nguyen, T | 1 |
| Liu, S | 1 |
| Bartis, J | 1 |
| Ellars, C | 1 |
| Edwards, S | 1 |
| Onthank, D | 1 |
| Silva, P | 1 |
| Yalamanchili, P | 1 |
| Robinson, S | 1 |
| Lazewatsky, J | 1 |
| Barrett, J | 1 |
| Bozarth, J | 1 |
| Tolvanen, T | 1 |
| Någren, K | 1 |
| Yu, M | 1 |
| Sutinen, E | 1 |
| Havu-Aurén, K | 1 |
| Jyrkkiö, S | 1 |
| Asola, M | 1 |
| Kotoneva, E | 1 |
| Nuutila, P | 1 |
| Minn, H | 1 |
| Jang, BS | 1 |
| Lim, E | 1 |
| Hee Park, S | 1 |
| Shin, IS | 1 |
| Danthi, SN | 1 |
| Hwang, IS | 1 |
| Le, N | 1 |
| Yu, S | 1 |
| Xie, J | 1 |
| Li, KC | 1 |
| Carrasquillo, JA | 1 |
| Paik, CH | 1 |
| Van Kuilenburg, AB | 1 |
| Stroomer, AE | 1 |
| Peters, GJ | 1 |
| Van Gennip, AH | 1 |
| Hull, WE | 1 |
| Port, RE | 1 |
| Herrmann, R | 1 |
| Britsch, B | 1 |
| Kunz, W | 1 |
| Naguib, FN | 1 |
| el Kouni, MH | 1 |
| Cha, S | 1 |
5 reviews available for beta-alanine and Neoplasms
| Article | Year |
|---|---|
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga | 2018 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration | 2013 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabiga | 2014 |
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga | 2014 |
[Metabolome analysis of solid tumors].
Topics: 4-Aminobutyrate Transaminase; beta-Alanine; Biomarkers, Tumor; Breast; Breast Neoplasms; Colonic Neo | 2016 |
14 other studies available for beta-alanine and Neoplasms
| Article | Year |
|---|---|
Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Female; Fluorouracil; Huma | 2021 |
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzi | 2014 |
Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2015 |
Selective N-alkylation of β-alanine facilitates the synthesis of a poly(amino acid)-based theranostic nanoagent.
Topics: Alkylation; Antineoplastic Agents, Phytogenic; beta-Alanine; Biopolymers; Cell Line, Tumor; Fluoresc | 2011 |
Carnosine and cancer: a perspective.
Topics: Animals; Antineoplastic Agents; beta-Alanine; Carnosine; Humans; Mice; Neoplasms | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart | 2012 |
Effect of beta-2-thienyl-DL-alanine on the growth of sarcoma T241 in C57 black mice.
Topics: Alanine; Animals; beta-Alanine; Black People; Humans; Mice; Neoplasms; Sarcoma; Sarcoma, Experimenta | 1953 |
Inhibitors of tumor growth: N-chloroacetyl-beta-alanine, N-chloroacetylglutamic acid, and azaserine.
Topics: Antineoplastic Agents; Azaserine; beta-Alanine; Humans; Neoplasms | 1960 |
Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy.
Topics: Adenocarcinoma; Animals; beta-Alanine; Binding, Competitive; Cell-Matrix Junctions; Dose-Response Re | 2003 |
Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.
Topics: Amino Acid Transport System A; beta-Alanine; Carbon Radioisotopes; Female; Humans; Male; Metabolic C | 2006 |
Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.
Topics: Animals; beta-Alanine; Humans; Indium Radioisotopes; Injections, Intraperitoneal; Integrin alphaVbet | 2007 |
Simultaneous determination of F-beta-alanine and beta-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Humans; Neoplasms; Reproducibility of Results; S | 2001 |
Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Topics: Aged; beta-Alanine; Blood Proteins; Chromatography, High Pressure Liquid; Female; Fluorides; Fluorou | 1988 |
Enzymes of uracil catabolism in normal and neoplastic human tissues.
Topics: Amidohydrolases; beta-Alanine; Dihydrouracil Dehydrogenase (NAD+); Fluorouracil; Humans; Kinetics; N | 1985 |